60

DAFTAR PUSTAKA

1. Adiyanti SS, Suryaatmadja M. 2016. Peran Galectin-3 sebagai Petanda

Fibrosis Jantung. Dalam: Sukartini N, Timan IS. Timan (Editor),

Pendidikan Berkesinambungan Patologi Klinik 2016. Jakarta: Departemen

Patologi Klinik Fakultas Kedokteran Universitas Indonesia.

2. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL,

et al. 2011. Predictive value of plasma galectin-3 levels in heart failure

with reduced and preserved ejection fraction. Annuals of Medicine, 43:60-

8.

3. Irmalita, Juzar DA, Andrianto, Setianto BY, Tobing DP, Firman D, et al.

2015. Pedoman Tatalaksana Sindrom Koroner Akut. Jakarta: PERKI.

4. Kumar A, Cannon CP. 2009. Acute Coronary Syndromes: Diagnosis and

Management, Part I. Mayo Clin Proc, 84(10):917-38.

5. Mendis S. 2014. Global target 1: A 25% relative reduction in overall

mortality from cardiovascular diseases, cancer, diabetes or chronic

respiratory diseases. Dalam: Armstrong T (Editor), Global Status Report

on Non Communicable Disease. Switzerland: WHO, p. 9-20.

6. Mihardja LK, Delima, Soetiarto F, Suhardi, Kristanto AY. 2013. Penyakit

tidak menular. Dalam: Kementerian Kesehatan Republik Indonesia,

penyunting. Riset Kesehatan Dasar. Jakarta: Badan Penelitian dan

Pengembangan Kesehatan Kementerian Republik Indonesia, p. 83-99.

7. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ.

2009. Galectin-3: a novel mediator of heart failure development and

progression. European Journal of Heart Failure, 11(9):811-7.

8. Salvagno GL, Pavan C. 2016. Prognostic biomarkers in acute coronary

syndrome. Ann Transl Med, 4(13):258

9. de Boer RA, Yu L, van Veldhuisen DJ. 2010. Galectin-3 in Cardiac

Remodeling and Heart Failure. Curr Heart Fail Rep, 7:1-8.

10. Santos-Gallego CG, Picatoste B, Badimon JJ. 2014. Pathophysiology of

Acute Coronary Syndrome. Curr Atheroscler Rep, 16:401.

11. Crea F, Liuzzo G. 2013. Pathogenesis of Acute Coronary Syndromes. J

Am Coll Cardiol, 61(1):1-11.

Universitas Kristen Maranatha

61

12. Kong P, Christia P, Frangogiannis NG. 2014. The pathogenesis of cardiac

fibrosis. Cell Mol Life Sci, 71(4):549-74.

13. Talman V, Ruskoaho H. 2016. Cardiac fibrosis in myocardial infarction—

from repair and remodeling to regeneration. Cell Tissue Res, 365(3):563-

81.

14. Drake RL, Vogl AW, Mitchell AWM. 2015. Gray’s Anatomy for

Students, Third Edition. Philadelphia: Churchill Livingstone.

15. Kierszenbaum AL, Tres LL. 2016. Histology and Cell Biology: An

Introduction to Pathology, Fourth Edition. Philadelphia: Elsevier

Saunders.

16. Costanzo LS. 2014. Physiology, Fifth Edition. Philadelphia: Saunders.

17. Tortora GJ, Derrickson B. 2012. Principles of Anatomy and Physiology,

Thirteenth Edition. Hoboken: John Wiley & Sons, Inc.

18. Thaler MS. 2013. Satu-satunya Buku EKG yang Anda Perlukan, Edisi 7.

Jakarta: EGC.

19. Barrett KE, Barman SM, Boitano S, Brooks HL. 2012. Ganong’s Review

of Medical Physiology, Twenty-Fourth Edition. New York: McGraw-Hill.

20. Sherwood L. 2010. Human Physiology: From Cells to Systems, Seventh

Edition. Belmont: Brooks/Cole.

21. Strom JB, Libby P. 2011. Atherosclerosis. Dalam: Lilly LS (Editor),

Pathophysiology of Heart Disease: A Collaborative Project of Medical

Students and Faculty, Fifth Edition. Philadelphia: Lippincott Williams &

Wilkins.

22. Rhee JW, Sabatine MS, Lilly LS. 2011. Acute Coronary Syndromes.

Dalam: Lilly LS (Editor), Pathophysiology of Heart Disease: A

Collaborative Project of Medical Students and Faculty, Fifth Edition.

Philadelphia: Lippincott Williams & Wilkins.

23. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula

J. 2010. Myocardial remodeling after infarction: the role of

myofibroblasts. Nat Rev Cardiol, 7:30-7.

24. Duan J, Gherghe C, Liu D, Hamlett E, Srikantha L, Rodgers L, et al. 2012.

Wnt1/bcatenin injury response activates the epicardium and cardiac

fibroblasts to promote cardiac repair. The EMBO Journal, 31(2):429-42.

Universitas Kristen Maranatha

62

25. Lajiness JD, Conway SJ. 2013. Origin, development, and differentiation of

cardiac fibroblasts. J Mol Cell Cardiol, 70:2-8.

26. Davis J, Molkentin JD. 2013. Myofibroblasts: Trust your heart and let fate

decide. J Mol Cell Cardiol, 70:9-18.

27. Frangogiannis NG. 2014. The inflammatory response in myocardial

injury, repair, and remodelling. Nat Rev Cardiol, 11:255-65.

28. Shinde AV, Frangogiannis NG. 2013. Fibroblasts in myocardial infarction:

a role in inflammation and repair. J Mol Cell Cardiol, 70:74-82.

29. Yang RY, Rabinovich GA, Liu FT. 2008. Galectins: structure, function

and therapeutic potential. Expert Reviews in Molecular Medicine, 10(17).

30. Eliaz I. 2013. The Role of Galectin-3 as a Marker of Cancer and

Inflammation in a Stage IV Ovarian Cancer Patient with Underlying Pro-

Inflammatory Comorbidities. Case Rep Oncol, 6:343-9.

31. Li LC, Li J, Gao J. 2014. Functions of Galectin-3 and Its Role in Fibrotic

Diseases. J Pharmacol Exp Ther, 351:336-43.

32. Weir RAP, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM,

et al. 2013. Galectin-3 and Cardiac Function in Survivor of Acute

Myocardial Infarction. Circ Heart Fail, 6:492-8.

33. Elabscience Biotechnology Inc. 2017. Human GAL3 (Galectin 3) ELISA

Kit: Instruction manual, 7th edition. Houston, TX.

34. Ducharme A, Tardif JC. 2017. Echocardiography in Patients with

Myocardial Infarction. Dalam Morrow D (Editor), Myocardial Infarction:

A Companion to Braunwald's Heart Disease. St. Louis: Elsevier.

35. Tumbelaka AR, Riono P, Sastroasmoro S, Wirjodiarjo M, Pudjiastuti P,

Firman K. 2011. Pemilihan Uji Hipotesis. Dalam: Sastroasmoro S, Ismael

S (Editor), Dasar-dasar Metodologi Penelitian Klinis Edisi ke-4. Jakarta:

Sagung Seto.

36. Tandon A, Villa CR, Hor KN, Jefferies JL, Gao Z, Towbin JA, et al. 2015.

Myocardial Fibrosis Burden Predicts Left Ventricular Ejection Fraction

and Is Associated With Age and Steroid Treatment Duration in Duchenne

Muscular Dystrophy. J Am Heart Assoc, 4:e001338.

37. Milano AD, Faggian G, Dodonov M, Golia G, Tomezzoli A, Bortolotti U,

et al. 2012. Prognostic value of myocardial fibrosis in patients with severe

aortic valve stenosis. J Thorac Cardiovasc Surg, 144:830-7.

Universitas Kristen Maranatha

63

38. Nucifora G, Aquaro GD, Pingitore A, Masci PG, Lombardi M. 2011.

Myocardial fibrosis in isolated left ventricular non-compaction and its

relation to disease severity. European Journal of Heart Failure, 13:170-6.

39. Rodriguez-Reyna TS, Morelos-Guzman M, Hernandez-Reyes P, Montero-

Duarte K, Martinez-Reyes C, Reyes-Utrera C, et al. 2015. Assessment of

myocardial fibrosis and microvascular damage in systemic sclerosis by

magnetic resonance imaging and coronary angiotomography.

Rheumatology, 54:647-54.

40. van Heerebeek L, Hamdani N, Handoko L, Falcao-Pires I, Musters RJ,

Kupreishvili K, et al. 2008. Diastolic Stiffness of the Failing Diabetic

Heart. Circulation, 117:43-51.

41. Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, Mauri F, et al. 2009.

Influence of Myocardial Fibrosis on Left Ventricular Diastolic: Non-

Invasive Assessment by CMR and ECHO. Circ Cardiovasc Imaging,

2(6):437-43.

42. Cameli M, Mondillo S, Righini FM, Lisi M, Dokollari A, Lindqvist P, et

al. 2016. Left Ventricular Deformation and Myocardial Fibrosis in Patients

With Advanced Heart Failure Requiring Transplantation. J Card Fail,

22(11):901-7.

43. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. 2012.

Galectin-3, A Marker of Cardiac Fibrosis, Predicts Incident Heart Failure

in the Community. J Am Coll Cardiol, 60(14):1249-56.

44. Chen K, Jiang RJ, Wang CQ, Yin ZF, Fan YQ, Cao JT, et al. 2013.

Predictive value of plasma galectin-3 in patients with chronic heart failure.

Eur Rev Med Pharmacol Sci, 17:1005-11.

45. Yalcin MU, Gurses K, Kocyigit D, Canpinar H, Canpolat U, Evranos B, et

al. 2015. The Association of Serum Galectin-3 Levels with Atrial

Electrical and Structural Remodeling. J Cardiovasc Electrophysiol,

26(6):635-40.

46. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi

JL. 2010. Galectin-3, cardiac structure and function, and long-term

mortality in patients with acutely decompensated heart failure. European

Journal of Heart Failure, 12:826-32.

47. Liu YH, D'Ambrosio M, Liao Td, Peng H, Rhaleb NE, Sharma U, et al.

2009. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling

and dysfunction induced by galectin-3, a mammalian adhesion/growth-

regulatory lectin. Am J Physiol Heart Circ Physiol, 296:H404-H412.

Universitas Kristen Maranatha

64

48. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi

S, et al. 2011. Galectin-3 Plasma Levels and Coronary Artery Disease: A

New Possible Biomarker of Acute Coronary Syndrome. Int J

Immunopathol Pharmacol, 24(4):905-13.

49. Winter MP, Wiesbauer F, Alimohammadi A, Blessberger H, Pavo N,

Schillinger M, et al. 2016. Soluble galectin-3 is associated with premature

myocardial infarction. Eur J Clin Invest, 46(5):386-91.

50. Gucuk IE, Akin SS, Kafes H, Basyigit F, Karalok N, Guray Y, et al. 2016.

Evaluation of galectin-3 levels in acute coronary syndrome. Ann Cardiol

Angeiol, 65(1):26-30.

51. Singsaas EG, Manhenke CA, Dickstein K, Orn S. 2016. Circulating

Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease,

but Are Not Influenced by Acute Myocardial Infarction. Cardiology,

134:398-405.

52. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald

E, et al. 2011. Galectin-3 and the Development of Heart Failure after

Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22.

Clinical Chemistry, 58(1):267-73.

Universitas Kristen Maranatha